Evidence map›Paper›PMID 40683874›Full record

ArticleCell death & disease2025

Identification of Nogo-B as a potential therapeutic target of osteosarcoma via stereochemically selective covalent probes.

Jian Xue, Meng Li, Li Kang, Meiting Wang, Jiabin Yin, Donghui Sun, Yaqi Deng, Qinghua Wei, Jiemin Wong, Tong Zhu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jian XueShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Meng LiShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Li KangShanghai Key Laboratory of Regulatory Biology, Fengxian District Central Hospital-ECNU Joint Center of Translational Medicine, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Meiting WangShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Jiabin YinShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Donghui SunShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Yaqi DengShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Qinghua WeiShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Jiemin WongShanghai Key Laboratory of Regulatory Biology, Fengxian District Central Hospital-ECNU Joint Center of Translational Medicine, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.ORCID http://orcid.org/0000-0002-5311-842X
Tong ZhuShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.ORCID http://orcid.org/0000-0001-7472-3736
Shunying LiuShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China. syliu@sist.ecnu.edu.cn.ORCID http://orcid.org/0000-0002-3894-757X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22071058
6 · The paper itself

Abstract

Osteosarcoma (OS) has been defined as one of the most intricate and formidable malignant bone tumors, and there has been no significant improvement in targeted therapies for OS over the past 50 years. Therefore, it is crucial to identify new potential drug targets for OS. Here, we have developed a label-free activity-based protein profiling (ABPP) using a stereochemically selective probe from an in-house patrimonial library of covalent small molecule compounds to identify an anti-OS target. Phenotypic screening resulted in the discovery of a selective inhibitor (S,R)-4v that potently suppresses the proliferation of OS 143B cells with an IC

Indexed as

Antineoplastic AgentsBone NeoplasmsNogo ProteinsOsteosarcomaApoptosisCell Line, TumorCell ProliferationHumansMolecular Docking SimulationNF-kappa BProto-Oncogene Proteins c-aktSignal TransductionStereoisomerismAntineoplastic AgentsNF-kappa BNogo ProteinsProto-Oncogene Proteins c-akt

Identifiers

PMID40683874
PMCPMC12276343

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.